Steve Brozak
Stock Analyst at WBB Securities
(0.49)
# 4,201
Out of 5,135 analysts
9
Total ratings
33.33%
Success rate
-13.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Brozak
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OMER Omeros | Reiterates: Strong Buy | $45 | $11.75 | +282.98% | 3 | Oct 15, 2025 | |
| CELU Celularity | Upgrades: Buy | $6 | $1.48 | +305.41% | 2 | Sep 9, 2025 | |
| MRKR Marker Therapeutics | Reiterates: Strong Buy | $13 | $1.50 | +733.33% | 1 | Apr 1, 2025 | |
| RDHL RedHill Biopharma | Downgrades: Buy | $17,000 → $16,000 | $1.00 | +1,607,940.20% | 3 | May 28, 2021 |
Omeros
Oct 15, 2025
Reiterates: Strong Buy
Price Target: $45
Current: $11.75
Upside: +282.98%
Celularity
Sep 9, 2025
Upgrades: Buy
Price Target: $6
Current: $1.48
Upside: +305.41%
Marker Therapeutics
Apr 1, 2025
Reiterates: Strong Buy
Price Target: $13
Current: $1.50
Upside: +733.33%
RedHill Biopharma
May 28, 2021
Downgrades: Buy
Price Target: $17,000 → $16,000
Current: $1.00
Upside: +1,607,940.20%